A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
This clinical trial is looking at a new targeted cancer drug called IDE849. It is designed for adults who have small cell lung cancer or other advanced tumours that produce a specific protein on their surface called DLL3. The trial is taking place in two early stages (Phase 1 and Phase 2). The main goals are to check if IDE849 is safe, find the best dose to give, and see how well it works on its own or alongside other cancer treatments like Imfinzi (durvalumab) and IDE161. Doctors will closely watch how the body breaks down the medicine and check whether the treatment can shrink tumours or stop them from growing. Taking part involves regular hospital visits for treatment, blood tests, and scans to monitor your health.
A colpo d'occhio
Di cosa tratta questo studio?
Small cell lung cancer and certain other fast-growing tumours can be very hard to treat, especially when standard therapies stop working. Researchers are constantly looking for new ways to target these cancer cells directly while sparing as much healthy tissue as possible. This study focuses on tumours that have a specific protein on their surface called DLL3, which is commonly found on small cell lung cancer cells.
The trial is testing an experimental medicine named IDE849. You can think of this medicine as a targeted guide: it is designed to seek out the DLL3 protein on cancer cells and deliver treatment straight to them. In this study, researchers will test IDE849 on its own and in combination with other anti-cancer drugs, including an immunotherapy called Imfinzi (durvalumab) and another study medicine called IDE161.
Because this is an early-phase trial, the primary aim is patient safety. Doctors need to find the right dose, understand what side effects might happen, and track how the drug moves through the body. At the same time, they will monitor whether the treatment helps shrink tumours or stops cancer from spreading.
Studies like this are crucial because they help discover whether new, targeted therapies could become useful future treatment options for people facing advanced cancer in the UK.
Punti chiave
- Tests a new targeted drug called IDE849 for tumours carrying the DLL3 protein.
- Aimed primarily at adults with advanced small cell lung cancer.
- Focuses on testing drug safety, finding the best dose, and tracking tumour response.
- Medicines are given by an intravenous drip at a hospital clinic.
- Participation is entirely voluntary and you can stop at any time.
Chi può essere idoneo?
This trial is open to adults aged 18 and over who have been diagnosed with an advanced solid tumour, such as small cell lung cancer, that produces the DLL3 protein. Your medical team can check whether your tumour has this marker by testing a small sample of tumour tissue.
Participants generally need to be well enough to carry out basic daily tasks and travel to hospital appointments. Usually, people joining this type of study have already tried standard cancer treatments that are no longer working, or there are no suitable standard options left.
You might not be able to join if you have certain active medical conditions, severe heart or lung problems, or if you are pregnant or breastfeeding. Your doctor will review your full medical history and current health to see if the trial is safe for you.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- You are aged 18 or older.
- You have small cell lung cancer or another tumour confirmed to express DLL3.
- Your cancer has continued to grow after standard treatments, or no standard options exist.
- You are well enough to attend regular hospital appointments.
- You are willing to have routine blood tests, scans, and infusions.
Cosa comporta la partecipazione?
If you join the trial, you will visit a specialist hospital centre regularly. Before you start, doctors will do tests such as blood work, heart checks, and body scans (CT or MRI) to make sure it is safe for you to take part. Treatment is given through a drip into a vein (an intravenous infusion), either on its own or together with the other study drugs. You will need to attend scheduled visits for your infusions, regular blood tests to check how the drug is handled by your body, and follow-up scans every few weeks to check your tumour. The study can last for several months or longer, and you can stay on the trial as long as the treatment continues to help you and side effects remain manageable.
Rischi e benefici potenziali
Luoghi (2)
- —Non verificatoFrancia
- —Non verificatoSpagna
Domande comuni
What is DLL3?
DLL3 is a protein found on the surface of certain cancer cells, particularly small cell lung cancer. The study drug is designed to recognise this protein and target the cancer.
Will I have to pay for the study treatment?
No. The trial medicine and all tests related to the study are provided free of charge.
Can I leave the trial if I change my mind?
Yes. You can withdraw from the study at any point without giving a reason, and your normal NHS care will continue as usual.
How often will I need scans?
You will usually have scans before you start and then every few weeks or months to see if the treatment is working.
Will I receive a placebo (dummy drug)?
No. In early trials like this, all participants receive active study medication; no dummy treatments are used.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.